α1受体阻滞剂与丹麦流感或肺炎住院成人30天死亡率和ICU入住风险的关联
该研究基于丹麦国家登记数据,纳入2005年1月1日至2018年11月30日因流感或肺炎住院的40岁及以上成人,随访至2018年12月31日,采用倾向评分加权比较当前使用α1受体阻滞剂者与未使用者及当前使用5α还原酶抑制剂者。共528467例患者(中位年龄75.0岁,四分位距64.4-83.6岁;男性273005例[51.7%]),其中21772例(4.1%)当前使用α1受体阻滞剂。倾向评分加权分析显示,α1受体阻滞剂组30天死亡率15.9%,未使用组18.5%,风险差-2.7%(95%CI -3.2%至-2.2%),RR 0.85(95%CI 0.83-0.88);ICU入住风险两组分别为7.3%和7.7%,风险差-0.4%(95%CI -0.8%至0%),RR 0.95(95%CI 0.90-1.00)。男性中α1受体阻滞剂组与5α还原酶抑制剂组比较,30天死亡率风险差-2.0%(95%CI -3.4%至-0.6%),RR 0.89(95%CI 0.82-0.96),ICU入住风险相似(风险差-0.3%[95%CI -1.4%至0.7%],RR 0.96[95%CI 0.83-1.10])。作者认为,α1受体阻滞剂的使用与流感或肺炎住院成人中的保护性获益相关。
要点
- 丹麦全国队列528467例流感或肺炎住院成人中,当前使用α1受体阻滞剂者30天死亡率15.9%,未使用者18.5%,RR 0.85(95%CI 0.83-0.88)。
- α1受体阻滞剂组ICU入住风险7.3%,未使用组7.7%,风险差-0.4%(95%CI -0.8%至0%),RR 0.95(95%CI 0.90-1.00),未达统计学显著。
- 男性中α1受体阻滞剂组与5α还原酶抑制剂组比较,30天死亡率风险差-2.0%(95%CI -3.4%至-0.6%),RR 0.89(95%CI 0.82-0.96)。
- 男性中α1受体阻滞剂组与5α还原酶抑制剂组ICU入住风险相似,风险差-0.3%(95%CI -1.4%至0.7%),RR 0.96(95%CI 0.83-1.10)。
- 作者认为,α1受体阻滞剂的使用与流感或肺炎住院成人中的保护性获益相关。
适用人群与场景
- 丹麦国家登记数据中2005年1月1日至2018年11月30日因流感或肺炎住院的40岁及以上成人,随访至2018年12月31日。
- 当前使用α1受体阻滞剂者与未使用者比较;未使用者定义为索引日期前365天内未配取α1受体阻滞剂处方。
- 当前使用α1受体阻滞剂者与当前使用5α还原酶抑制剂者比较(男性分析)。
研究设计与关键结果
- 研究类型:基于丹麦国家登记数据的人群队列研究;共528467例成人患者(中位年龄75.0岁,四分位距64.4-83.6岁;男性273005例[51.7%])。
- 暴露:当前使用α1受体阻滞剂21772例(4.1%),与经倾向评分加权至α1受体阻滞剂组倾向评分分布的未使用α1受体阻滞剂者22117例比较。
- 主要终点30天死亡率:α1受体阻滞剂组15.9% vs 未使用组18.5%,风险差-2.7%(95%CI -3.2%至-2.2%),RR 0.85(95%CI 0.83-0.88)。
- 次要终点ICU入住风险:α1受体阻滞剂组7.3% vs 未使用组7.7%,风险差-0.4%(95%CI -0.8%至0%),RR 0.95(95%CI 0.90-1.00)。
- 男性亚组:当前使用α1受体阻滞剂18280例 vs 倾向评分加权后当前使用5α还原酶抑制剂18228例,30天死亡率风险差-2.0%(95%CI -3.4%至-0.6%),RR 0.89(95%CI 0.82-0.96)。
- 男性亚组ICU入住风险:α1受体阻滞剂组 vs 5α还原酶抑制剂组风险差-0.3%(95%CI -1.4%至0.7%),RR 0.96(95%CI 0.83-1.10)。
证据类型、等级与局限
- 证据类型:基于丹麦国家登记数据的人群队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,α1受体阻滞剂的使用与流感或肺炎住院成人中的保护性获益相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Alpha 1-adrenergic receptor blocking agents (α1-blockers) have been reported to have protective benefits against hyperinflammation and cytokine storm syndrome, conditions that are associated with mortality in patients with coronavirus disease 2019 and other severe respiratory tract infections. However, studies of the association of α1-blockers with outcomes among human participants with respiratory tract infections are scarce.
OBJECTIVE: To examine the association between the receipt of α1-blockers and outcomes among adult patients hospitalized with influenza or pneumonia.
DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study used data from Danish national registries to identify individuals 40 years and older who were hospitalized with influenza or pneumonia between January 1, 2005, and November 30, 2018, with follow-up through December 31, 2018. In the main analyses, patients currently receiving α1-blockers were compared with those not receiving α1-blockers (defined as patients with no prescription for an α1-blocker filled within 365 days before the index date) and those currently receiving 5α-reductase inhibitors. Propensity scores were used to address confounding factors and to compute weighted risks, absolute risk differences, and risk ratios. Data were analyzed from April 21 to December 21, 2020.
EXPOSURES: Current receipt of α1-blockers compared with nonreceipt of α1-blockers and with current receipt of 5α-reductase inhibitors.
MAIN OUTCOMES AND MEASURES: Death within 30 days of hospital admission and risk of intensive care unit (ICU) admission.
RESULTS: A total of 528 467 adult patients (median age, 75.0 years; interquartile range, 64.4-83.6 years; 273 005 men [51.7%]) were hospitalized with influenza or pneumonia in Denmark between 2005 and 2018. Of those, 21 772 patients (4.1%) were currently receiving α1-blockers compared with a population of 22 117 patients not receiving α1-blockers who were weighted to the propensity score distribution of those receiving α1-blockers. In the propensity score-weighted analyses, patients receiving α1-blockers had lower 30-day mortality (15.9%) compared with patients not receiving α1-blockers (18.5%), with a corresponding risk difference of -2.7% (95% CI, -3.2% to -2.2%) and a risk ratio (RR) of 0.85 (95% CI, 0.83-0.88). The risk of ICU admission was 7.3% among patients receiving α1-blockers and 7.7% among those not receiving α1-blockers (risk difference, -0.4% [95% CI, -0.8% to 0%]; RR, 0.95 [95% CI, 0.90-1.00]). A comparison between 18 280 male patients currently receiving α1-blockers and 18 228 propensity score-weighted male patients currently receiving 5α-reductase inhibitors indicated that those receiving α1-blockers had lower 30-day mortality (risk difference, -2.0% [95% CI, -3.4% to -0.6%]; RR, 0.89 [95% CI, 0.82-0.96]) and a similar risk of ICU admission (risk difference, -0.3% [95% CI, -1.4% to 0.7%]; RR, 0.96 [95% CI, 0.83-1.10]).
CONCLUSIONS AND RELEVANCE: This cohort study's findings suggest that the receipt of α1-blockers is associated with protective benefits among adult patients hospitalized with influenza or pneumonia.
参考来源
- Thomsen RW, Christiansen CF, Heide-Jørgensen U, et al. Association of α1-Blocker Receipt With 30-Day Mortality and Risk of Intensive Care Unit Admission Among Adults Hospitalized With Influenza or Pneumonia in Denmark. JAMA Netw Open. 2021. PMID: 33566109. doi:10.1001/jamanetworkopen.2020.37053
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。